Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Type - Eylea | Lucentis | Beovu
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP33243
Newly-released Anti-Vascular Endothelial Growth Factor Therapeutics Market industry analysis report by Persistence Market Research shows that global sales in 2021 were held at US$ 11.9 Bn. With a CAGR of 0.9%, the projected market growth during 2022-2032 is expected to be slightly higher than the historical growth.
The Anti-Vascular Endothelial Growth Factor Therapeutics Market is accounted to give an absolute dollar opportunity growth of nearly US$ 1.1 Bn during 2022 – 2032. Eylea is expected to be the highest revenue-generating product type.
|
Attribute |
Details |
|
Global Market Size (2022) |
US$ 12 Bn |
|
Global Market Size (2032) |
US$ 13.1 Bn |
|
Global Market CAGR (2022 – 2032) |
0.9% |
|
U.S. Market CAGR (2022 – 2032) |
1% |
|
Key Companies Profiled |
|
As per the Anti-Vascular Endothelial Growth Factor Therapeutics industry research by Persistence Market Research - market research and competitive intelligence provider, historically, from 2015 to 2021, the market value increased at around 0.7% CAGR, wherein, countries such as the U.S., China, Japan, South Korea, and the UK held a significant share in the global market.
The market for anti-Vascular Endothelial Growth Factor therapies is anticipated to continue growing as eye diseases such as retinal vein occlusion, diabetic retinopathy, macular edema, and Age-Related Macular Degeneration (AMD) become more common, and those suffering from aging are at risk of developing these ailments.
Angiogenesis Inhibitors, also known as Anti-Vascular Endothelial Growth Factor Inhibitors, stop new blood vessels from growing. Angiogenesis inhibitors are useful in the treatment of cancer, macular degeneration, and other illnesses involving blood vessel proliferation. The action of endogenous stimulators and inhibitors regulates the production of ANTI-VEGF or angiogenesis.
Endogenous inhibitors are proteins found in the body that regulate the development of blood vessels. The cellular matrix and basement protein contain endogenous inhibitors. ANTI-VEGF is the most powerful angiogenesis factor, with high levels of expression in ovarian, endometrial, and cervical cancers.
Anti-ANTI-VEGF/anti-angiogenesis factors limit the synthesis of pro-angiogenic factors, preventing them from attaching to their receptors and thereby inhibiting angiogenesis. Monoclonal antibodies against ANTI-VEGF or ANTI-VEGFR, soluble ANTI-VEGFR hybrids, and tyrosine kinase inhibitors are the most frequent treatments for ANTI-VEGF pathway suppression. Bevacizumab, a monoclonal antibody, is the most commonly utilized treatment.
The rise in cancer prevalence around the world, as well as knowledge of the therapeutic prospects given by oncology medicines, has prompted the pharmaceutical sector to develop new cancer treatments. According to the World Health Organization, new cancer cases are predicted to increase by 70% in the next two decades. Because around 60% of malignant tumors exhibit high levels of ANTI-VEGF, finding a treatment strategy to block the ANTI-VEGF tumor-causing pathway has become a top priority for all researchers.
One of the largest hindrances to the Anti-Vascular Endothelial Growth Factor Therapeutics inhibitors becoming a gold standard in cancer treatment is that angiogenesis is not the main cause of tumor growth.
Diabetic retinopathy screening and diagnosis rates in developing nations are low, limiting market expansion. Another factor limiting overall growth is the risk of intraocular damage associated with anti-ANTI-VEGF therapy.
Diabetes mellitus is a critical medical condition that affects more than 350 million people globally. The most frequent microvascular consequence of diabetes, diabetic retinopathy (DR), is the primary cause of new instances of blindness in working-age individuals. Diabetic macular edema (DME) is a vision-limiting consequence of diabetes that affects roughly 30% of patients with diabetes for at least 20 years and is responsible for much of the vision loss associated with the disease.
The development of ANTI-VEGF as a key pathophysiologic mediator of DME suggested the issue that anti-ANTI-VEGF medication administered to the eye could enhance visual results in this condition. To present, four distinct ANTI-VEGF inhibitors have been evaluated in prospective, randomized phase II or phase III clinical trials in patients with DME, each provided through intraocular injection.
The findings show that treatment with anti-ANTI-VEGF medicines improves visual and anatomic outcomes significantly when compared to laser photocoagulation while avoiding the ocular adverse effects associated with laser treatment. As a result, ANTI-VEGF medication has become the main treatment option for many patients with DME.
According to figures from the United Nations Department of Economic and Social Affairs, the world's elderly population (those aged 60 and up) numbered around 703 million in 2019. In 2018, the proportion of people aged 65 and up was 6%, but in 2019 it grew to 9%. In 2017, the aging population was over 69 million, 549 million, 183 million, 78 million, and over 76 million, in Africa, Asia, Europe, North America, and Latin America, respectively, according to the United Nations. As a result, the market will be driven by the growing geriatric population.
Furthermore, the incidence of eye problems is expected to rise in the coming years as the senior population grows. According to WHO projections, the population of individuals over 60 has surpassed that of children under the age of five. The geriatric population is expected to reach over 2 billion by 2050, up from 900 million in 2015. Furthermore, there are 125 million persons in the world who are 80 years old or older.
Which Region is projected to offer the Largest Opportunity for the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The market for Anti-Vascular Endothelial Growth Factor Therapeutics in North America is growing at a steady pace. In 2021, North America had the highest revenue share of more than 40%. The growing geriatric population and regulatory clearances are responsible for the region's substantial share. Research and innovation are being aided by increased access to large historical data in the sector. The American College of Cardiology (ACC) announced a suite of cardiovascular data registries in April 2021, allowing healthcare companies to assess and improve service quality using existing data.
U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis
The market in the United States with a CAGR of 0.7% during the 2015-2021 period and the expected market of US$ 4.6 Bn by 2032 is the key market. The rising frequency of cardiovascular illnesses, the increased risk of obesity, rising disposable incomes, and the presence of multiple market competitors are some of the primary drivers of the market in the country.
U.K. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis
The market in the U.K. is expected to reach a valuation of US$ 527 Mn by 2032. With a projected CAGR of 0.9% during the forecast period, the market in the country is expected to gross an absolute dollar opportunity of around US$ 22 Mn during the forecast period.
Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis
In Japan, the market is expected to reach a valuation of US$ 455 Mn by 2032. The market is expected to garner an absolute dollar opportunity of around US$ 50 Mn, growing at a CAGR of 1.2% during 2022 – 2032.
Why Eylea is gaining the Utmost Traction in the Anti-Vascular Endothelial Growth Factors Therapeutics Market?
By 2020, the Eylea category dominated the global market. Throughout the forecast period, the category is expected to remain dominant. The development of formulations and the emergence of sophisticated drug delivery technologies have motivated an increase in demand. Bayer AG announced the launch of Eylea prefilled syringes in Europe in April 2020, with complete coverage of all 27 member states.
Why Age-related Macular Degeneration (AMD) is considered a critical disease type while curing vision loss?
This condition obliterates center vision, making everyday tasks like reading, driving, and recognizing faces more difficult. There are two types of AMD: moist and dry. While dry AMD causes gradual vision loss, wet AMD causes vision loss that is more severe and is the most advanced type of illness. Wet AMD was once thought to be incurable, and two-thirds of people diagnosed might expect to be legally blind within two years of diagnosis.
Because of the emergence of injectable anti-vascular endothelial growth factor (anti-ANTI-VEGF) medicines, the tale of wet AMD has changed dramatically. In some countries, the use of anti-ANTI-VEGF medications has nearly halved the prevalence of AMD-related blindness, and ophthalmologists can now assist wet AMD patients to keep, and in some cases restoring their vision.
The key companies operating in the Anti-Vascular Endothelial Growth Factors Therapeutics Market are F. Hoffmann-La Roche Ltd., Biogen, Pfizer, Inc., CoherusBioSciences, and Amgen, Inc.
According to a WHO report published in 2021, over 196 million individuals worldwide are affected by AMD, with around 10.4 million instances resulting in moderate to severe vision impairment. As a result, the rise in ophthalmic disorders will necessitate the use of Anti-Vascular Endothelial Growth Factor Therapeutics in the future, which will serve as a catalyst for the Anti-Vascular Endothelial Growth Factor Therapeutics business.
Some of the recent developments of Anti-Vascular Endothelial Growth Factor Therapeutics Market providers are as follows:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies offering the Anti-Vascular Endothelial Growth Factor Therapeutics Market, which are available in the full report.
By Product Type
By DiseaseType
By Region
To know more about delivery timeline for this report Contact Sales
The Anti-Vascular Endothelial Growth Factor Therapeutics Market is worth US$ 11.9 Bn at present.
The Anti-Vascular Endothelial Growth Factor Therapeutics Market is projected to increase at a CAGR of around 0.9% during 2022 – 2032.
The value of the Anti-Vascular Endothelial Growth Factor Therapeutics Market increased at a CAGR of around 0.7% during 2015 – 2021.
Eylea has better stats when compared with other product types in the year 2021.
Anti-VEGF drug use has risen sharply and continues to rise year after year which is a key trend shaping the growth of the Anti-Vascular Endothelial Growth Factor Therapeutics Market.
The top 5 countries driving the demand for the Anti-Vascular Endothelial Growth Factor Therapeutics Market are the U.S., China, Japan, South Korea, and the UK.
The market for Anti-Vascular Endothelial Growth Factor Therapeutics Market is projected to expand at a CAGR of around 1.2% during 2022 – 2032 in China.
While the market in South Korea is expected to grow at nearly 0.9%, the market in Japan is projected to register growth at a CAGR of nearly 1.2% during 2022 - 2032.
